Trinity Biotech (TRIBY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY)

TRIB 0.889

-1.3%

Nov 12 3:32 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Findit who wrote (9361)	5/31/1998 11:02:00 AM
From: dowman	Read Replies (2) of 14328

This is one item regarding this company that is troublesome and not consistent with effective communication. Almost all companies break down sales by product lines. They have consistently talked about selling 90 different tests in most countries in the world, but break down 90 tests and $16 million in revenue and it is obvious something is missing. They are not selling equal amounts of these tests( works out to less than 200,000 per test and hardly worth the effort). And it is not the type of test that is supposedly the competitive advantage, as most of their tests are not new. It is their technology that is supposed to be their edge. Thus revealing sales numbers by product line reveals next to nothing to potential competitors. I have owned this stock in the past (and others in this field. Most have been very poor investments for a variety of reasons.) and would buy again, but only when they start to give the kind of information that is common in most public companies. I have watched this company closely as an owner, and now from the sidelines. Another troubling aspect was the major press release about insiders buying the stock. That is the kind of information that is usually found in required SEC documents, not announced during trading hours. As they do not file the same documents as domestic companies, shareholders do not have the following information. Was this an open market purchase, or exercise of options. If options, what was the exercise price. And what requirements do they have as far as a holding period. Where is the report by the company of these details. Not a verbal comment from them, or their PR people, but in the annual or quarterly or the equivalent to a 10k or 10q filing that domestic companies have to file. I would be glad to buy this stock back if there was hard information from the company on many of these issues. I sold because they seem reluctant to talk about some very basic issues that shareholders need to know to make intelligent decisions. If someone can provide this information from an official company document I will be glad to adjust my thinking

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next